drugset

drugset / Trial / NCT00380835

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

NCT00380835 ↗

Phase 2 Withdrawn 66 enrolled Celgene Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.

Timeline

Start: —
Primary completion: —
Completion: 2007-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amrubicin	Small molecule	—	—

Indications